Travere Therapeutics, Inc.
TVTX
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients witā¦ read more
Healthcare
Biotechnology
13 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$34.97
Price+1.72%
$0.59
1Y
Price
Market Cap
$3.129b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years+26.8%
EBITDA Margin+15.6%
Net Profit Margin+8.6%
Free Cash Flow MarginRevenue
$435.827m
+86.9%
1y CAGR+60.0%
3y CAGR+40.8%
5y CAGREarnings
-$88.539m
+72.5%
1y CAGR-18.7%
3y CAGR-27.7%
5y CAGREPS
-$1.06
+74.0%
1y CAGR-10.8%
3y CAGR-19.4%
5y CAGRBook Value
$73.564m
$538.581m
Assets$465.017m
Liabilities$329.749m
DebtDebt to Assets
61.2%
-14.6x
Debt to EBITDAFree Cash Flow
-$80.334m
+76.3%
1y CAGR+7.0%
3y CAGR-107.5%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company